Corcept Therapeutics Incorporated (NASDAQ: CORT) said after the markets closed on December 11 that its phase II trial evaluating its cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS) did not meet its primary endpoint.